application for kras g12c inhibitors and methods

application for kras g12c inhibitors and methods

  • us patent application for kras g12c inhibitors and methods of using the same patent application (application #20200069657 issued march 5, 2020

    US Patent Application for KRAS G12C INHIBITORS AND METHODS OF USING THE SAME Patent Application (Application #20200069657 issued March 5, 2020

    Provided herein are methods of treating cancer with KRAS G12C inhibitors and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  • us patent application for inhibitors of kras g12c and methods of using the same patent application (application #20200207766 issued july 2, 2020

    US Patent Application for INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME Patent Application (Application #20200207766 issued July 2, 2020

    Provided herein are methods of using KRAS G12C inhibitors. These methods of using the inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers. Synthesis of Disclosed Compounds Compounds as

  • us patent application for kras g12c inhibitors and methods of using the same patent application (application #20180177767 issued june 28, 2018

    US Patent Application for KRAS G12C INHIBITORS AND METHODS OF USING THE SAME Patent Application (Application #20180177767 issued June 28, 2018

    Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers. RELATED APPLICATIONS This appli

  • us patent application for kras g12c inhibitors patent application (application #20190270743 issued september 5, 2019) - justia patents search

    US Patent Application for KRAS G12C INHIBITORS Patent Application (Application #20190270743 issued September 5, 2019) - Justia Patents Search

    The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of

  • us patent application for kras g12c inhibitors patent application (application #20200115375 issued april 16, 2020) - justia patents search

    US Patent Application for KRAS G12C INHIBITORS Patent Application (Application #20200115375 issued April 16, 2020) - Justia Patents Search

    Justia Patents US Patent Application for KRAS G12C INHIBITORS Patent Application (ApplicationWO2015/054572 and WO2016/164675 disclose certain quinazoline derivatives capable of binding to KRas G12C. WO2016/044772 also discloses methods of .

  • wo2018119183a2 - kras g12c inhibitors and methods of using the same - google patents

    WO2018119183A2 - Kras g12c inhibitors and methods of using the same - Google Patents

    Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  • us patent application for kras g12c inhibitors patent application (application #20190144444 issued may 16, 2019) - justia patents search

    US Patent Application for KRAS G12C INHIBITORS Patent Application (Application #20190144444 issued May 16, 2019) - Justia Patents Search

    The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of

  • wo2019217691a1 - kras g12c inhibitors for the treatment of cancer - google patents

    WO2019217691A1 - Kras g12c inhibitors for the treatment of cancer - Google Patents

    Provided herein are KRAS G12C inhibitors of the general formula (I) and pharmaceutical compositions comprising the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  • mutation-specific approaches to kras cancers: what we can learn from g12c-directed inhibitors - national cancer institute

    Mutation-Specific Approaches to KRAS Cancers: What We Can Learn from G12C-Directed Inhibitors - National Cancer Institute

    As mentioned above, the redox-sensitivity of KRAS G12C may limit reaction of the KRAS G12C thiol to covalent modification by inhibitors due to direct competition with cellular oxidants. In-cell studies may be insufficient to test competition of

  • wellspring biosciences announces clearance of ind application to initiate phase 1 trial of kras g12c mutant inhibitor ars-3248

    Wellspring Biosciences Announces Clearance of IND Application to Initiate Phase 1 Trial of KRAS G12C Mutant Inhibitor ARS-3248

    16/5/2019 · Scientists at both Wellspring and Janssen have made significant contributions in the discovery and development of potent, selective KRAS G12C inhibitors. 1 J. M. Ostrem et al., Nature 2013; 503

  • kras g12c inhibitors and methods of using the same (amgen)

    Kras G12c Inhibitors And Methods Of Using The Same (Amgen)

    28/6/2018 · Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  • covalent inhibitors of kras

    Covalent inhibitors of KRAS

    Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisom

  • (pdf) potent and selective covalent quinazoline inhibitors of kras g12c

    (PDF) Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C

    Human lung cancer cell lines, including KRAS G12C cell lines (H358, H23, Calu-1, H1792, H2122), A549 (KRAS G12S), H441 (KRAS G13V), and KRAS WT (PC9, HCC827) were authenticated.and obtained from

  • allele-specific inhibitors inactivate mutant kras g12c by a trapping mechanism | science

    Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism | Science

    (D) The effect of inhibitors targeting tyrosine kinases on the antiproliferative effect of KRAS G12C inhibition in KRAS G12C mutant cell lines (n = 3 replicates, mean and SEM). The concentrations of the inhibitors used in (C) and (D) are noted

  • a potent kras macromolecule degrader specifically targeting tumours with mutant kras | nature communications

    A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS | Nature Communications

    26/6/2020 · The effect of the KRAS degrader on RAS downstream signalling pathways of various cell lines was examined by Western blot analysis: a H358 (KRAS G12C), b MIA PaCa-2 (KRAS G12C), c A549 (KRAS G12S

  • clinical pharmacogenomic testing of kras, braf and egfr mutations by high resolution melting analysis and ultra-deep pyrosequencing | bmc cancer

    Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing | BMC Cancer

    For KRAS, six types of substitutions were detected (17 G12D, 9 G13D, 7 G12C, 2 G12A, 2 G12V, 2 G12S), while V600E accounted for all the BRAF activating mutations. Regarding EGFR, two cases showed exon 19 deletions (delE746-A750 and